Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 1/2011

01-03-2011 | Special Article

Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only)

Authors: Fausto Roila, David Warr, Matti Aapro, Rebecca A. Clark-Snow, Larry Einhorn, Richard J. Gralla, Jorn Herrstedt, Mitsue Saito, Maurizio Tonato

Published in: Supportive Care in Cancer | Special Issue 1/2011

Login to get access

Abstract

Purpose

An update of the recommendations for the prophylaxis of delayed emesis induced by moderately emetogenic chemotherapy discussed during the third Perugia Consensus Conference (June 2009) sponsored by MASCC–ESMO was presented. The review considered new studies published since the second consensus conference (April 2004).

Methods

An online search was used conducting PubMed and the search terms moderately, chemotherapy, and emesis with a restriction to papers in English.

Results

Overall, nine randomized controlled studies were included: four evaluating NK1 receptor antagonists, one palonosetron, and four dopamine receptor antagonists.

Conclusions

In patients receiving a combination of anthracycline plus cyclophosphamide treated with a combination of aprepitant, a 5-HT3 receptor antagonist and dexamethasone to prevent acute nausea and vomiting, aprepitant is suggested to prevent delayed emesis. In patients who do not receive aprepitant for the prophylaxis for acute emesis and in which palonosetron is recommended, a multiday oral dexamethasone is the preferred treatment for the prevention of delayed emesis. Levels of evidence and of consensus for both recommendations are moderate.
Literature
1.
Roila F, Hesketh PJ, Herrstedt J (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17(1):20–28PubMedCrossRef
2.
Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24(18):2932–2947PubMedCrossRef
3.
ASHP (1999) Therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm 56(8):729–764
4.
Herrstedt J, Roila F (2009) Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol 20(Suppl 4):156–158PubMed
5.
NCCN practice guidelines in oncology: antiemesis V.3.2009
6.
Roila F, Warr D, Clark-Snow RA, Tonato M, Gralla RJ, Einhorn LH et al (2005) Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer 13(2):104–108PubMedCrossRef
7.
Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23(12):2822–2830PubMedCrossRef
8.
Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W et al (2009) A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat 113(3):529–535PubMedCrossRef
9.
Rapoport BL, Jordan K (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 188(4):423–431CrossRef
10.
Herrstedt J, Apornwirat W, Shaharyar A, Aziz Z, Roila F, Van Belle S et al (2009) Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol 27(32):5363–5369PubMedCrossRef
11.
Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10(2):115–124PubMedCrossRef
12.
Hickok JT, Roscoe JA, Morrow GR, Bole CW, Zhao H, Hoelzer KL et al (2005) 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol 6(10):765–772PubMedCrossRef
13.
Lindley C, Goodin S, McCune J, Kane M, Amamoo MA, Shord S et al (2005) Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone. Am J Clin Oncol 28(3):270–276PubMedCrossRef
14.
Bloch J, Rixe O, Meric JB, Delgado A, Khayat D (2005) Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy. Curr Med Res Opin 21(11):1763–1771PubMedCrossRef
15.
Khamales S, Bethune-Volters A, Chidiac J, Bensaoula O, Delgado A, Di Palma M (2006) A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis. Anticancer Drugs 17(2):217–224PubMedCrossRef
Metadata
Title
Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only)
Authors
Fausto Roila
David Warr
Matti Aapro
Rebecca A. Clark-Snow
Larry Einhorn
Richard J. Gralla
Jorn Herrstedt
Mitsue Saito
Maurizio Tonato
Publication date
01-03-2011
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue Special Issue 1/2011
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-010-1039-y

Other articles of this Special Issue 1/2011

Supportive Care in Cancer 1/2011 Go to the issue

Special Article

Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy

Meeting Highlight

Prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Guideline update and results of the Perugia consensus conference

Special Article

Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—state of the art

Special Article

Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009

Special Article

Acute emesis: moderately emetogenic chemotherapy

Special Article

Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits